Related Experiment Videos
Transient acantholytic dermatosis induced by recombinant human interleukin 4
S J Mahler1, R L De Villez, D R Pulitzer
1Division of Dermatology, University of Texas Health Science Center, San Antonio 78284-7876.
Journal of the American Academy of Dermatology
|August 1, 1993
Summary
Interleukin 4 (IL-4) can cause a skin condition called transient acantholytic dermatosis. This study details the clinical and histological features of this rare drug-induced eruption.
Area of Science:
- Immunology
- Dermatology
- Cytokine research
Background:
- Interleukin 4 (IL-4) is a cytokine implicated in various diseases.
- Transient acantholytic dermatosis (TAD) has an unclear etiology and is not typically associated with drug ingestion or immunological factors.
Observation:
- Three patients developed a pruritic papulovesicular eruption after receiving intravenous recombinant human IL-4.
- Clinical and histological examination revealed features consistent with TAD.
- No other known triggers for TAD were identified in these patients.
Findings:
- Recombinant human IL-4 can induce a cutaneous eruption clinically and histologically resembling TAD.
- This represents the first reported cutaneous side effect of IL-4 therapy.
- The mechanism may involve antibody-mediated effects or increased tissue-type plasminogen activator production.
Implications:
- Highlights a novel cutaneous adverse effect of IL-4.
- Suggests a potential immunologic basis or plasminogen activator involvement in TAD.
- Informs clinical monitoring for patients receiving IL-4 therapy.